Skip to main content

Table 3 Prognostic factors by Cox’s univariate analysis for relapse-free survival

From: Prognostic factors of patients with left-sided obstructive colorectal cancer: post hoc analysis of a retrospective multicenter study by the Japan Colonic Stent Safe Procedure Research Group

Variable

Survival (mo) Av. (95% CI)

HR

95% CI

p value

Kaplan-Meier method

Cox’s univariate analysis

Performance status (ECOG)

   

0.523

 0–1 (n=262)

62.0 (57.4–66.5)

1

  

 2–4 (n=39)

59.9 (48.5–71.2)

0.845

0.505–1.416

 

Location

   

0.381

 Colon (n=273)

62.1 (57.6–66.5)

1

  

 Rectum (n=28)

57.7 (44.2–71.1)

0.381

0.433–1.377

 

Decompression for BTS

   

0.155

 No (n=80)

63.0 (56.0–70.0)

1

  

 Yes (n=221)

60.7 (55.6–65.7)

0.724

0.463–1.130

 

Change in the decompression method

   

0.005

 No (n=282)

63.8 (59.4–68.2)

1

  

 Yes (n=19)

35.5 (22.3–48.7)

0.422

0.232–0.769

 

Depth of invasion

   

<0.001

 T3 (n=179)

68.5 (63.3–73.7)

1

  

 T4 (n=121)

49.5 (43.2–55.9)

0.489

0.338–0.708

 

Lymph node metastasis

   

0.177

 N0 (n=164)

65.1 (59.5–70.7)

1

  

 N1-2 (n=137)

58.4 (52.1–64.8)

0.776

0.536–1.122

 

Lymph node metastasis (excluding Stage II cases with <12 harvested lymph nodes)

   

0.036

 N0 (n=130)

69.3 (63.4–75.1)

1

  

 N1-2 (n=137)

58.9 (52.5–65.2)

0.644

0.427–0.971

 

Postoperative complication

   

0.026

 grade 0-I (n=219)

64.9 (59.8–69.9)

1

  

 grade II-V (n=82)

54.0 (45.7–62.3)

1.553

1.053–2.289

 

Adjuvant chemotherapy

   

0.616

 No (n=153)

60.5 (54.6–66.4)

1

  

 Yes (n=148)

63.9 (58.0–69.8)

1.048

0.872–1.264

 

Adjuvant chemotherapy in Stage II

   

0.214

 No (n=113)

63.8 (58.0–69.6)

1

  

 Yes (n=51)

59.8 (49.1–70.6)

0.707

0.409–1.222

 

Adjuvant chemotherapy in Stage III

   

0.003

 No (n=40)

44.3 (32.6–56.0)

1

  

 Yes (n=97)

63.4 (56.7–70.0)

2.231

1.312–3.791

 

Preoperative serum CEA level (ng/mL)

   

0.224

 ≤ 5 (n=124)

59.6 (54.2–65.0)

1

  

 > 5 (n=167)

59.4 (53.5–65.2)

0.787

0.535–1.158

 

Preoperative serum CA 19-9 level (U/mL)

   

0.226

 ≤ 37 (n=239)

63.1 (58.3–68.0)

1

  

 > 37 (n=50)

53.4 (43.9–62.9)

0.748

0.468–1.196

 

Preoperative NLR

 ≤ 3 (n=113)

59.4 (53.0–65.9)

1

 

0.957

 > 3 (133)

60.9 (54.3–67.5)

1.011

0.674–1.518

 

 ≤ 5 (n=188)

59.2 (54.1–64.3)

1

 

0.798

 > 5 (n=58)

61.8 (52.4–71.2)

1.064

0.660–1.716

 
  1. Survival (mo) Av. (95% CI) survival periods (months) average and 95% confidential interval, HR hazard ratio, ECOG Eastern Cooperative Oncology Group, BTS bridge to surgery, SEMS self-expanding metallic stent, TADT transanal decompression tube, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, NLR neutrophil-to-lymphocyte ratio